Patents by Inventor William GO
William GO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082307Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: ApplicationFiled: August 24, 2023Publication date: March 14, 2024Applicants: Kite Pharma, Inc., Ofc of Tech Transfer, NIHInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Patent number: 11779601Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: GrantFiled: May 27, 2016Date of Patent: October 10, 2023Assignees: Kite Pharma, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20230158075Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: September 27, 2022Publication date: May 25, 2023Applicants: Kite Pharma Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Patent number: 11491187Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: April 10, 2018Date of Patent: November 8, 2022Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20220169694Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.Type: ApplicationFiled: February 20, 2021Publication date: June 2, 2022Inventors: Adrian Bot, John Rossi, Vicki Plaks, Szu-Ting Chou, William Go, Jenny Jiyun Kim
-
Patent number: 10322146Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: July 13, 2017Date of Patent: June 18, 2019Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20180369283Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: April 10, 2018Publication date: December 27, 2018Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20180344767Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.Type: ApplicationFiled: May 27, 2016Publication date: December 6, 2018Applicants: Kite Pharma, Inc., The United States of America as represented by the Secretary Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Patent number: 9855298Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: May 27, 2016Date of Patent: January 2, 2018Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Publication number: 20170368101Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: July 13, 2017Publication date: December 28, 2017Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
-
Publication number: 20160346326Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: ApplicationFiled: May 27, 2016Publication date: December 1, 2016Applicants: Kite Pharma, Inc., National Cancer InstituteInventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
